Table 1 Descriptive characteristics of COVID-19-positive patients enrolled in the study.
From: Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients
Characteristics (n = 462) | Asymptomatic (n = 78) | Mildly symptomatic (n = 200) | Severely symptomatic (n = 122) | Critically ill (n = 62) | ||
|---|---|---|---|---|---|---|
Number of released | 78 (100.0%) | 200 (100.0%) | 119 (97.5%) | 39 (62.9%) | ||
Number of deceased | 0 | 0 | 3 (2.6%) | 23 (37.1%) | ||
Sex | Female/deceased | 49 (62.8%) / 0 | 142 (71.0%) / 0 | 51 (41.8%) / 1 (0.8%) | 23 (37.1%) / 7 (11.3%) | |
Male / deceased | 29 (37.2%) / 0 | 58 (29.0%) / 0 | 71 (58.2%) / 2 (1.6%) | 39 (62.9%) / 16 (25.8%) | ||
Age, years (mean) | 56.5 ± 23.2 | 48.1 ± 17.2 | 68.8 ± 16.5 | 66.5 ± 18.2 | ||
Number of patients < 65 years / deceased | 48 (61.5%) / 0 | 167 (83.5%) / 0 | 50 (41.0%) / 0 | 26 (41.9%) / 1 (1.6%) | ||
Number of Patients ≥ 65 years / deceased | 30 (38.5%) / 0 | 33 (16.5%) / 0 | 72 (59.0%) / 3 (2.5%) | 36 (58.1%) / 22 (35.5%) | ||
Vaccination (n = 457) | None | 47 (61.8%) | 157 (78.5%) | 78 (65.5%) | 45 (72.6%) | |
1 dose | 10 (13.2%) | 10 (5.0%) | 15 (12.6%) | 9 (14.5%) | ||
2 doses | 20 (26.3%) | 33 (16.5%) | 29 (24.3%) | 8 (12.9%) | ||
3 doses | 1 (1.3%) | 0 | 0 | 0 | ||
